IBAT Inhibitors
2 drugsAbout IBAT
The ileal bile acid transporter (IBAT) is responsible for reabsorbing bile acids in the small intestine, which is crucial for cholesterol levels and fat digestion.
IBAT is a drug target where modulation of bile acid metabolism is desired; however, there is currently no genetic evidence directly linking IBAT to specific diseases.
IBAT is targeted by two FDA-approved small molecule drugs: BYLVAY (IPSEN) and LIVMARLI (MIRUM), both approved in 2021 for other indications.
Top IBAT Drugs
The competitive landscape consists of two companies, IPSEN and MIRUM, with approved IBAT-targeting drugs.
The concentrated market suggests high barriers to entry, requiring strong differentiation for new entrants.
IBAT Drug Modality Landscape
Modalities
Routes of Administration
IBAT is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or biologics could offer differentiation and new IP opportunities.
IBAT Clinical Trials 18 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IBAT. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 6 | 3 | 0 | 3 | 100% |
| Phase 3 | 10 | 6 | 1 | 3 | 86% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved IBAT drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting IBAT. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
IBAT Drug Approval Timeline (2021 - 2021)
The first and most recent drug approvals for IBAT occurred in 2021.
Recent approvals indicate a growing interest in IBAT as a target, but also suggest the market may be approaching saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 5 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IBAT. A trial counts if an approved drug acting on IBAT is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.